Clinical Trials Directory

Trials / Unknown

UnknownNCT01687010

Diagnostic and Prognostic Value of Combination Biomarkers in the Critically Ill Patient With Sepsis.

Status
Unknown
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Jianfeng Xie · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Sepsis is a common cause for morbidity and mortality in critically ill patients. With the development of medical skills, the mortality is still remain very high. Inappropriateness of initial antibiotic treatment is an important risk factor for mortality and effective antimicrobial administration within the first hour of documented hypotension was associated with increased survival to hospital discharge in adult patients with septic shock. However, the early treatment based on early diagnosis.But it is very difficult to diagnosis because of lack of specific clinic symptom and sign.When severe sepsis occur, biomarker could be helpful to diagnosis. Unfortunately, the diagnostic value of single biomarker is limited. Therefore, combine several biomarkers could enhance the diagnostic value.

Conditions

Timeline

Start date
2012-03-01
Completion
2012-10-01
First posted
2012-09-18
Last updated
2012-09-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT01687010. Inclusion in this directory is not an endorsement.

Diagnostic and Prognostic Value of Combination Biomarkers in the Critically Ill Patient With Sepsis. (NCT01687010) · Clinical Trials Directory